Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer

Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia

Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité – Universitätsmedizin Berlin

Actimed Therapeutics to present at upcoming Bio-Europe conference as one of 'Scrip’s 10 to watch'

Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China

Actimed Therapeutics appoints Annalisa Jenkins as Advisor

Actimed Therapeutics appoints Robin Bhattacherjee as CEO